This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Insulin-like growth factor I (IGF-I) is produced in response to pituitary growth hormone (GH) and is a major regulator of growth. Some children have IGF-I deficiency because they cannot respond to their own GH. They have severe growth retardation unresponsive to conventional therapies. This study evaluates the safety and efficacy of recombinant human IGF-I (rhIGF-I) given to short children with growth hormone insensitivity. Children must have clinically documented GH insensitivity with serum IGF-I levels that are low for age, normal GH secretion and evidence for failure of GH action, or have developed GH-neutralizing antibodies during GH treatment. Once enrolled, children are treated with subcutaneous injection of rhIGF-I twice daily until they reach final height. The primary efficacy endpoint is growth rate. Subjects are evaluated a minimum of every 6 months. Safety measures include monitoring of blood chemistries, kidney and spleen growth, and cardiac function.
Showing the most recent 10 out of 502 publications
